All In Biotech

Drug Trial Radar · NCT00332436

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: May 30, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 586 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

586

Actual

Start

Dec 1999

Primary completion

Nov 2001

Study completion Nov 2001

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 1, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension

Conditions

  • Ocular Hypertension

Interventions

  • brimonidine/timolol fixed combinationDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IOP

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Louisville, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.